News Related to BriaPro Therapeutics

Related coverage linked through entity extraction aliases.

BriaCell Transfers Soluble CD80 License to BriaPro; Four Posters Accepted at AACR 2026

Mar 10, 2026

BriaCell Therapeutics announced an asset purchase agreement transferring its Soluble CD80 license to majority-owned subsidiary BriaPro, while four abstracts were accepted for presentation at the 2026 AACR Annual Meeting.

BriaCell spins off sCD80 cancer therapy to BriaPro subsidiary

Feb 14, 2026

BriaCell Therapeutics transfers exclusive license for Soluble CD80 cancer therapy to subsidiary BriaPro in deal valued at C$1.18 million, with BriaCell retaining 78% stake and providing $3 million credit facility.